Please wait a minute...
Reviews in Cardiovascular Medicine  2018, Vol. 19 Issue (S1): 1-8     DOI: 10.3909/ricm19S1S0004
Review | Next articles
Identifying Patients for Nonstatin Therapy
Jennifer G. Robinson1, Karol E. Watson2
1 Departments of Epidemiology & Medicine, University of Iowa College of Public Health and Carver College of Medicine, Iowa City, IA
2 Departments of Medicine & Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA
Download:  PDF(951KB)  ( 189 )
Export:  BibTeX | EndNote (RIS)      
Abstract:

Statins are first-line therapy for reducing atherosclerotic cardiovascular disease (ASCVD) risk. Some patients remain at high ASCVD risk despite maximizing statin therapy. Ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) have been shown to reduce ASCVD events in randomized trials and may be of benefit in selected high-risk patients with cardiovascular disease (CVD) or familial hypercholesterolemia (FH). Number-needed-to-treat (NNT) to prevent one ASCVD event can help identify groups of patients who may gain a net benefit from added nonstatin therapy. Patient groups with NNTs <25 (in whom PCSK9 mAbs may approach cost effectiveness with discounting) include extremely high-risk patients (those with CVD with FH, polyvascular disease, or recurrent ASCVD events) with lowdensity lipoprotein cholesterol (LDL-C) levels ≥70 mg/dL, very high-risk patients (those with CVD with diabetes [and no polyvascular disease], chronic kidney disease, or acute coronary syndromes, or CVD or FH with poorly controlled risk factors) with LDL-C levels ≥100 mg/dL, and high-risk patients (those with CVD or FH with well-controlled risk factors) with LDL-C ≥130 mg/dL. Ezetimibe, which is generic in the United States, is reasonable for patient groups with NNTs <30, the level considered reasonable by most patients. This includes extremely high-risk patients with LDL-C levels ≥130 mg/dL, or very high-risk patients with LDL-C ≥190 mg/dL. All guidelines recommend statin therapy for the prevention of ASCVD.

Key words:  Atherosclerotic cardiovascular disease      PCSK9 monoclonal antibodies      Nonstatin therapy      Cholesterol-lowering therapies     
Published:  20 January 2018     

Cite this article: 

Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm19S1S0004     OR     https://rcm.imrpress.com/EN/Y2018/V19/IS1/1

[1] Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B): 2889-2934.
[2] Boden WE, Probstfield JL, Anderson T, et al; AIMHIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365: 2255-2267.
[3] Landray MJ, Haynes R, Hopewell JC, et al; HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropriprant in high-risk patients. N Engl J Med. 2014; 371: 203-2012.
[4] Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-1574.
[5] Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016; 68: 2412-2421.
[6] Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387-2397.
[7] Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376: 1713-1722.
[8] Jones PH, Bays HE, Chaudhari U, et al. Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials. Am J Cardiol. 2016; 118: 1805-1811.
[9] Steel N. Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. BMJ l. 2000; 320: 1446-1447.
[10] Tice JA, Ollendorf D, Chapman R, et al. Evolocumab for treatment of high cholesterol: effectiveness and value. Institue for Clinical and Economic Review website. https://icer-review.org/wp-content/uploads/2017/06/ICER_PCSK9_NEU_091117.pdf. Published September 11, 2017. Accessed January 24, 2018.
[11] Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278
[12] Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1500-1509.
[13] Robinson JG, Farnier M, Krempf M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1489-1499.
[14] Ridker PM, Revkin J, Amarenco P, et al; SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017; 376: 1527-1539.
[15] Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5: 941-950.
[16] Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2017; 137: 338-350.
[17] Tice JA, Kazi DS, Pearson SD. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value. JAMA Intern Med. 2016; 176: 107-108.
[18] LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352: 1425-1435.
[1] Jennifer G. Robinson, Karol E. Watson. Can We Cure Atherosclerosis?[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 20-24.
[2] Boback Ziaeian, John Dinkler, Karol Watson. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 125-130.
[3] Norman E. Lepor, Laurn Contreras, Chirag Desai, Dean J. Kereiakes. The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 290-309.
[4] Karol E. Watson, Eric H. Stocker, Douglas S. Jacoby, Peter A. McCullough. Advanced Lipid Testing: When, Why, and In Whom?[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 310-319.
[5] Divya Ratan Verma, Eliot A. Brinton. Management of Hypercholesterolemia for Prevention of Atherosclerotic Cardiovascular Disease: Focus on the Potential Role of Recombinant Anti-PCSK9 Monoclonal Antibodies[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 86-101.
No Suggested Reading articles found!